| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 65
| Issue : 5 | Page : 50-58 |
|
|
Paediatric type diffuse high grade gliomas in the WHO CNS5 classification: What the pathologist needs to know?
Shruti Rao, Ayushi Sahay, Sridhar Epari
Department of Pathology, Tata Memorial Hospital and ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
Correspondence Address:
Sridhar Epari
8th Floor, Annexe Building, Tata Memorial Hospital, Dr E. Borges Road, Parel, Mumbai – 400 012, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijpm.ijpm_1202_21
|
|
|
Pediatric-type of diffuse high-grade gliomas (HGG) are classified as a distinct group in the current fifth edition of WHO classification. This group of high-grade tumors is no more called as glioblastoma (GBM), which has been reserved for adult isocitrate dehydrogenase (IDH)-wild type HGG. These tumors are uncommon as compared to embryonal tumors and low-grade gliomas (LGG). Pediatric-type of diffuse HGG biologically differs from their adult counterparts in that they are therapeutically less sensitive to alkylating chemotherapies. They comprise a heterogeneous group of molecularly defined tumors – predominantly histone gene altered, less common receptor tyrosine kinase (RTK)-mediated, and syndrome-associated. This review provides an overview of these uncommon tumors and discusses the diagnostic approach of this heterogeneous group of tumors.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
